Financials data is unavailable for this security.
View more
Year on year Zhejiang Starry Pharmaceutical Co Ltd grew revenues 3.04% from 2.13bn to 2.20bn while net income improved from a loss of 75.85m to a gain of 44.23m.
| Gross margin | 22.38% |
|---|---|
| Net profit margin | 1.33% |
| Operating margin | 1.75% |
| Return on assets | 0.56% |
|---|---|
| Return on equity | 1.43% |
| Return on investment | 1.13% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at Zhejiang Starry Pharmaceutical Co Ltd fell by 125.61m. Cash Flow from Financing totalled 83.01m or 3.78% of revenues. In addition the company generated 44.55m in cash from operations while cash used for investing totalled 253.99m.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 6.16 |
|---|---|
| Tangible book value per share | 4.54 |
More ▼
Balance sheet in CNYView more
| Current ratio | 1.00 |
|---|---|
| Quick ratio | 0.6491 |
| Total debt/total equity | 1.09 |
|---|---|
| Total debt/total capital | 0.5201 |
More ▼
Growth rates in CNY
Year on year, growth in dividends per share fell -100.00% while earnings per share excluding extraordinary items rose 158.23%. Additionally, five year annualized earnings per share growth ranks below the industry average relative to its peers.
| Div yield(5 year avg) | 0.68% |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 0.00% |
| EPS growth(5 years) | -14.61 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 130.25 |
More ▼
